Suppr超能文献

玻璃体内注射甲氨蝶呤治疗非霍奇金眼内淋巴瘤

Management of non Hodgkin's intraocular lymphoma with intravitreal methotrexate.

作者信息

de Smet M D

机构信息

Department of Ophthalmology, University of Amsterdam, Amsterdam.

出版信息

Bull Soc Belge Ophtalmol. 2001(279):91-5.

Abstract

Intraocular non Hodgkin's lymphoma has traditionally been treated with radiotherapy or systemic chemotherapeutic agents. Unfortunately, radiotherapy rarely leads to a long term remission, and can only be safely administered once. Systemic chemotherapy has limited intraocular penetration. Intravitreal administered methotrexate is highly effective at inducing remission and is well tolerated. A case report is presented of a recurrent intraocular lymphoma following radiotherapy and systemic chemotherapy which responded to a combination of intravitreal methotrexate and dexamethasone. A response was seen within three weeks of treatment initiation. Toxicity was limited to the progression of a pre-existing cataract. Review of the literature shows that intravitreal methotrexate is well tolerated, with few acute complications. However, with monotherapy, local recurrences have been observed.

摘要

眼内非霍奇金淋巴瘤传统上采用放射治疗或全身化疗药物进行治疗。不幸的是,放射治疗很少能导致长期缓解,且只能安全使用一次。全身化疗的眼内穿透性有限。玻璃体内注射甲氨蝶呤在诱导缓解方面非常有效,且耐受性良好。本文报告了一例放疗和全身化疗后复发的眼内淋巴瘤患者,该患者对玻璃体内注射甲氨蝶呤和地塞米松联合治疗有反应。治疗开始后三周内即见疗效。毒性仅限于原有白内障的进展。文献综述表明,玻璃体内注射甲氨蝶呤耐受性良好,急性并发症很少。然而,采用单一疗法时,已观察到局部复发情况。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验